drugset / Trial / NCT05760378
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the Famitinib with Camrelizumab plus treatment of physician's choice (TPC) versus Camrelizumab plus TPC in Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.
Timeline
- Start
- 2023-03-17
- Primary completion
- 2025-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | — | — |
| Background | Camrelizumab | Monoclonal antibody | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Eribulin | Small molecule | — | — |
| Background | nab-Palitaxel | Unknown | — | — |